FDA clears RSB Spine's Interplate C-Ti as an anterior cervical plate

NewsGuard 100/100 Score

RSB Spine, LLC, today announced that the InterPlate® C-Ti has been cleared for a new indication. When reclassification of interbody fusion devices occurred in 2007, the C-Ti was the first system cleared by the U.S. Food and Drug Administration. With this most recent announcement, the C-Ti has now become the first interbody fusion device to be cleared as an anterior cervical plate as well.

RSB Spine Chief Executive Officer John A. Redmond said: "We are excited about this new clearance for a number of reasons. As the name implies, we have always been of the opinion that the InterPlate C-Ti can function as an interbody device or a cervical plate. It has the advantages of both without any of the drawbacks of either, so this indication is appropriate. The new indication for use also simplifies coding for our surgeons."

Robert S. Bray Jr., M.D., is the inventor of the InterPlate and has performed over 9,000 spine surgeries. He is the Founding Director and CEO of D.I.S.C. Sports and Spine Center, a state-of-the-art outpatient surgery center in Marina del Rey, CA. Dr. Bray said: "The RSB InterPlate C-Ti gives surgeons a number of options and the new classification allows the codes for surgery to match its true application. Considering our clinical experience thus far and the C-Ti's ease of use, it should be even more widely accepted." Dr. Bray has invented a number of other commercially successful medical devices.

Source:

RSB Spine, LLC

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Female ginseng compound holds promise as osteoporosis treatment